RxDoctor Payments Data

Juan Ramirez, MD

Family Medicine · Huntington Park, CANPI 1285654350

Payments from drug & device makers

$1,750in general payments, 2019–2025

Across 84 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$385
  • Johnson & Johnson$178
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$173
  • Amarin Pharma, Inc.$152
  • Dexcom, Inc.$143
  • Sanofi-aventis U.S. LLC$141
  • plus $577 from 8 others

What the payments were for

  • Food & beverage$1,750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,750 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$12,262
Medicare patients
31
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$59,948
EliquisApixaban45$45,830
JanuviaSitagliptin Phosphate37$30,025
JanumetSitagliptin Phos/Metformin Hcl19$28,807
RybelsusSemaglutide11$24,574
EntrestoSacubitril/Valsartan16$23,677
OzempicSemaglutide21$20,234
KerendiaFinerenone18$17,121
TradjentaLinagliptin15$10,737
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$7,347
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,706
Levothyroxine Sodium298$5,582
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$4,331
Atorvastatin Calcium294$4,232
Dexlansoprazole DrDexlansoprazole13$3,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$123$70,68473 claims
MerckJanuvia, Janumet$35$58,83256 claims
Novo NordiskRybelsus, Ozempic$385$44,80832 claims
NovartisEntresto$97$23,67716 claims
BayerKerendia$99$17,12118 claims
Lilly USA, LLCHumulin N$127$2,60924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Huntington Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →